Dr. Camidge on the FDA Approval of Pembrolizumab for Squamous NSCLC
October 31st 2018D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses the FDA approval of first-line pembrolizumab (Keytruda) in metastatic squamous non–small cell lung cancer regardless of PD-L1 expression.
Read More
Dr. Camidge on the KEYNOTE-024 Trial in NSCLC
August 23rd 2018D. Ross Camidge, MD, PhD, professor, Division of Medical Oncology, Joyce Zeff Chair in Lung Cancer Research, School of Medicine, Division of Medical Oncology, University of Colorado, discusses implications of the KEYNOTE-024 trial in non–small cell lung cancer (NSCLC).
Read More
Dr. Camidge on the ALTA Study of Brigatinib in NSCLC
October 16th 2017D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses the results of the ALTA trial, which is exploring brigatinib (Alunbrig) in patients with ALK-positive non-small cell lung cancer.
Read More
Dr. Camidge on MET as a Target in Lung Cancer
April 23rd 2015D. Ross Camidge, MD, director, Thoracic Oncology Clinical Program, program director, Thoracic Oncology Clinical and Translational Research Fellowship, University of Colorado Denver, discusses MET and if it is still a relevant target in lung cancer.
Read More
Dr. Camidge on AP26113 in Advanced Malignancies
October 7th 2013D. Ross Camidge, MD, PhD, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies.
Read More